차바이오텍

085660KOSDAQ

45.5 / 100

Reference Date: 2026-10-23

Financial Score17.0 / 40

News Sentiment12.5 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Declined 5.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cha BioTech primarily operates in umbilical cord blood storage, stem cell research, cell therapy development, anti-aging services, and consulting. The company also engages in pharmaceuticals, global CDMO, and international healthcare network expansion through its major subsidiaries. In 2024, revenue was distributed as 61.06% in medical services, 10.43% in product sales, and 28.51% in other services.

Number of Employees

354people

Average Salary

51.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.85Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

-19.32Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

51.30Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼252.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 7,400Won52-week high 23,85052-week low 7,360

1-month return2.0Point

1m -5.61% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral[기재정정]타인에대한담보제공결정2026-10-16
Neutral[기재정정]타인에대한담보제공결정2026-09-30
Neutral[기재정정]타인에대한담보제공결정2026-09-28